Perrigo Co. PLC (0Y5E)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 15.78 |
|---|---|
| 52-week range | 8.85 – 20.12 |
| Return, 1 month / 3 months | +9.7% / +62.5% |
| Return, 1 year / 3 years | −19.0% / −40.5% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 57.4% |
| Worst drawdown (1 year) | -55.9% |
| Average daily value traded | 0.04M USD |
| Dividend yield | 7.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Perrigo Company makes store-brand and generic healthcare products. It supplies retailers and pharmacies with over-the-counter medicines such as pain relievers, cough and cold remedies, and digestive treatments, along with infant formula and other consumer health items. It also produces generic prescription medicines and active pharmaceutical ingredients. The company is incorporated in Ireland and runs its main operations from the United States, serving customers across North America and Europe.
The shares are listed on the London Exchange in UK under the code 0Y5E, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Perrigo Co. PLC (0Y5E) trades on the London Exchange in UK. It last closed at USD 15.78 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,892 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 19.0% and over the last three months it rose 62.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 31.0% | ||
| From 52-week high | -21.3% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 62.5% | ||
| 6-month return | 40.0% | ||
| 12-month return, skipping the last month | -26.1% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 57.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -55.9% | ||
| Liquidity | 22 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.04M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 89 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.4% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −0.7% |
|---|---|
| 1 month | +9.7% |
| 3 months | +62.5% |
| 6 months | +40.0% |
| 1 year | −19.0% |
| 3 years | −40.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 14.38 / 12.04 |
|---|---|
| Golden / death cross (60 days) | Golden, 32 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.68 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Aug 2026 | EUR 0.2900 |
| 28 May 2026 | EUR 0.2900 |
| 2 Mar 2026 | EUR 0.2900 |
| 28 Nov 2025 | EUR 0.2900 |
| 29 Aug 2025 | EUR 0.2900 |
| 30 May 2025 | EUR 0.2900 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.